Orasis reports positive results for eye drop to treat presbyopia

Orasis Pharmaceuticals announced that its phase 3 trials showed patients treated with CSF-1 achieved a statistically significant three-line or more gain in distance-corrected near visual acuity with no loss of distance visual acuity.
The data from the NEAR-1 and NEAR-2 trials, which involved 613 subjects, will be the basis for U.S. regulatory submission in the second half of 2022, the company said in a press release.
CSF-1, a 0.4% pilocarpine HCl solution, met its primary and key secondary endpoints on day 8, according to the release. Pooled across the two studies, 40% and 50% of subjects

Orasis Pharmaceuticals announced that its phase 3 trials showed patients treated with CSF-1 achieved a statistically significant three-line or more gain in distance-corrected near visual acuity with no loss of distance visual acuity.
The data from the NEAR-1 and NEAR-2 trials, which involved 613 subjects, will be the basis for U.S. regulatory submission in the second half of 2022, the company said in a press release.
CSF-1, a 0.4% pilocarpine HCl solution, met its primary and key secondary endpoints on day 8, according to the release. Pooled across the two studies, 40% and 50% of subjects